Bright Uro

Executive Summary

Bright Uro is a San Francisco-based medical device company pioneering the Glean Urodynamics System (UDS), the first FDA-cleared, wireless, and catheter-free diagnostic tool for lower urinary tract symptoms. By replacing traditional invasive urodynamic testing, the Glean system aims to improve diagnostic accuracy, patient comfort, and clinical workflow efficiency. The company addresses a significant unmet need in urology, where current testing is often painful and burdensome. With FDA clearance already achieved, Bright Uro is poised to commercialize its innovative platform, targeting urology clinics and hospitals. The company's focus on patient-centric design and streamlined data capture positions it to capture market share in the urodynamics market, estimated at over $300 million annually. Key challenges include adoption by clinicians and reimbursement coverage, but the product's clear advantages over legacy systems provide a strong value proposition.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch and initial sales traction of Glean UDS70% success
• Q4 2026Publication of clinical data from user studies or trials80% success
• 2027Securing CPT code(s) or reimbursement coverage for wireless urodynamics50% success